In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Pfizer released positive top line results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide). 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
The European Medicines Agency (EMA) has accepted for review the Marketing Authorization Applications for AVT03, a proposed biosimilar candidate to the Prolia and Xgeva (denosumab), submitted by Germany’s STADA Arzneimittel. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Bayer has entered into a collaboration with MOMA Therapeutics to develop a small molecule oncology program using the latter’s proprietary KNOMATIC platform. 9 October 2024
Genor Biopharma has announced plans for a significant merger with Edding Group, marking one of the first reverse takeovers involving a Hong Kong-listed biopharma company. 8 October 2024
China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and supply agreement with US major Amgen. 8 October 2024
Germany’s Eckert & Ziegler, a specialist in radioisotopes for medical, scientific and industrial applications, has announced a global clinical supply agreement with GlyTherix, an Australian targeted radiotherapy firm specializing in developing antibody radiopharmaceuticals for solid tumors. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Daejeon-based Orum Therapeutics, a specialist in degrader-antibody conjugates (DAC), has filed for an initial public offering (IPO) on South Korea's Kosdaq market. 7 October 2024
Mosaic Therapeutics, a UK-based oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, has announced the appointment of Barry Davies as chief scientific officer. 7 October 2024
The National Institute for Health and Care Excellence (NICE) has issued its Final Appraisal Determination (FAD) to not recommend US biotech major Celgene’s Abraxane (nab-paclitaxel) in combination with gemcitabine, for adults with previously untreated metastatic adenocarcinoma of the pancreas (metastatic pancreatic cancer). 17 September 2015
Amgen has entered into a definitive acquisition agreement to acquire Dezima, a privately-held, Netherlands-based biotechnology company focused on developing innovative treatments for dyslipidemia. 16 September 2015
US drug major AbbVie submitted a supplemental New Drug Application (sNDA) to the US Food and Drug Administration requesting a new indication for Imbruvica (ibrutinib). 14 September 2015
With over 800 new drugs in various stages of research, US pharmaceutical companies have firmly positioned themselves for continued innovation to treat cancer, the second leading cause of death in the country. 10 September 2015
Genentech, a unit of Swiss pharma major Roche, has been granted priority review by the US Food and Drug Administration for its alectinib for ALK-positive, locally advanced or metastatic non-small-cell lung cancer. 10 September 2015
Shares in Theravance closed down over 14% overnight on the Nasdaq stock exchange after the company said its inhaled medicine Breo (fluticasone/ vilanterol) failed to extend life of patients with chronic respiratory disease in a clinical trial involving 16, 485 people. 9 September 2015
AstraZeneca has announced updated, encouraging data on AZD9291 (osimertinib) in first-line patients with epidermal growth factor receptor mutation (EGFRm) positive advanced non-small cell lung cancer (NSCLC) and previously treated patients with EGFR T790M mutation-positive NSCLC. 9 September 2015
The global market value for non-small cell lung cancer (NSCLC) treatment will rise from $a value of 6.9 billion in 2014 to $10.9 billion by 2021, representing a compound annual growth rate (CAGR) of 8.5%, according to new research. 9 September 2015
Helsinn Group has entered into an exclusive distribution and license agreement with BIAL for the exclusive distribution and licence rights to anamorelin in Spain, Portugal, Angola and Mozambique. 8 September 2015
Bristol-Myers Squibb has released positive updated results from the Opdivo (nivolumab)+Yervoy (ipilimumab) arms in CheckMate -012, a multi-arm Phase Ib trial evaluating Opdivo in patients with chemotherapy-naïve advanced non-small cell lung cancer (NSCLC). 8 September 2015
Anglo-Swedish drug major AstraZeneca on Tuesday said it has signed a five-year £11.5 million ($17.4 million), clinical trial bioinformatics agreement with the University of Manchester in a bid to deliver personalized health care to cancer patients. 8 September 2015
The UK’s National Institute for Health and Care Excellence has recommended Keytruda (pembrolizumab) from Merck & Co for treating advanced skin cancer. 7 September 2015
Chinese specialty drugmaker Yabao Pharmaceutical and the University of South Australia, have announced an important new collaboration to develop new treatments for cancer. 7 September 2015
Biotech firms Pelago Bioscience and Biovica have agreed to work together to provide a common platform for developing new oncology drugs and treatments. 7 September 2015
On Friday, NHS England announced the de-listing of expensive cancer drugs, in the wake of an “overspent” Cancer Drugs Fund. In total, 17 cancer drugs for 25 different indications will no longer be paid for in future, effective November. 5 September 2015
The UK subsidiary of Japanese drug major Astellas Pharma breached Clause 2 of the ABPI Code of Practice and is the subject of advertisements in the medical, pharmaceutical and nursing press. 4 September 2015
Incyte Corp has entered into a global license and collaboration agreement with Chinese drugmaker Jiangsu Hengrui Medicine for the development and commercialization of SHR-1210. 3 September 2015